Cohance Lifesciences Limited

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, was established in 1989 and is headquartered in Hyderabad, India. The company specializes in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and formulated drugs. Its diverse product portfolio includes small molecule APIs, advanced intermediates, antibody drug conjugates, high-purity oligonucleotide building blocks, pellets, finished dosage forms, and specialty chemicals such as agrochemicals.

In May 2025, the company rebranded from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited, reflecting its expanded capabilities and strategic direction. As of March 2026, Cohance Lifesciences Limited is a publicly listed entity on the National Stock Exchange of India (NSE) under the ticker symbol COHANCE and on the Bombay Stock Exchange (BSE) under the ticker symbol 543064. The company has a paid-up capital of ₹3,432.79 crore and an authorized capital of ₹3,499.94 crore.

Cohance Lifesciences Limited operates multiple manufacturing facilities across India, specializing in the production of APIs and finished pharmaceutical formulations. These facilities are equipped with advanced technologies to ensure high-quality standards and compliance with international regulatory requirements. The company's manufacturing units are strategically located to serve both domestic and international markets, facilitating efficient distribution and supply chain management.

The leadership team at Cohance Lifesciences Limited is headed by Managing Director and Chief Executive Officer, Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju. The Chief Financial Officer is Himanshu Agarwal, who oversees the company's financial operations. Other key executives include Yann D'Herve, Chief Executive Officer of the CDMO Business, and K.P. Ravinatha Shetty, Platform Chief Operating Officer. The company also has a dedicated Head of Investor Relations, Cyndrella Carvalho, and a Chief Quality and Compliance Officer, Dr. K. Nagendra Babu.

Cohance Lifesciences Limited has a significant presence in regulated markets, including the United States, Europe, the United Kingdom, and Australia. The company has obtained approvals for its APIs and finished dosage forms from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals enable Cohance to market its products in these regions, adhering to stringent quality and safety standards. The company's commitment to regulatory compliance is further demonstrated by its adherence to Good Manufacturing Practices (GMP) and other relevant guidelines.

Cohance Lifesciences Limited has strategically expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and enhancing its global reach. By obtaining WHO prequalification, Cohance ensures that its products meet international quality standards, thereby gaining the trust of healthcare providers and patients in these markets.

Cohance Lifesciences Limited's geographic strategy involves a balanced approach to market diversification and risk management. While the company has a strong presence in regulated markets, it continues to explore opportunities in emerging markets to drive growth and mitigate concentration risks. This strategic direction reflects Cohance's commitment to expanding its global footprint and enhancing its competitive position in the pharmaceutical industry.

Cohance Lifesciences Limited's manufacturing facility in Hyderabad, India, is registered with the U.S. Food and Drug Administration (FDA). The company has received a warning letter from the FDA dated January 30, 2026, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA identified issues related to inadequate investigations into product quality complaints and insufficient cleaning and maintenance of manufacturing equipment. Cohance has acknowledged these observations and is committed to implementing corrective actions to address the FDA's concerns.

Cohance Lifesciences Limited's manufacturing facilities comply with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. The company's products are prequalified by the WHO, ensuring they meet international quality standards. This compliance facilitates access to global markets and underscores Cohance's commitment to maintaining high-quality manufacturing practices.

In India, Cohance Lifesciences Limited holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO). The company also possesses approvals from state drug controllers and export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets. These regulatory approvals affirm Cohance's adherence to national standards and its capability to supply quality pharmaceutical products globally.

On January 30, 2026, the FDA issued a warning letter to Cohance Lifesciences Limited, citing violations of CGMP regulations. The FDA identified issues related to inadequate investigations into product quality complaints and insufficient cleaning and maintenance of manufacturing equipment. Cohance has acknowledged these observations and is committed to implementing corrective actions to address the FDA's concerns.

Cohance Lifesciences Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products and services. The company's focus on complex chemistries and end-to-end contract development and manufacturing organization (CDMO) services differentiates it from competitors. Cohance's extensive product portfolio, including APIs, advanced intermediates, and finished dosage forms, positions it as a comprehensive solution provider in the pharmaceutical sector.

Cohance Lifesciences Limited's key differentiators include its expertise in complex chemistries, robust research and development capabilities, and a comprehensive product portfolio spanning APIs, advanced intermediates, and finished dosage forms. The company's commitment to quality and regulatory compliance, as evidenced by its adherence to WHO and EU GMP standards, further distinguishes it in the pharmaceutical industry.

Cohance Lifesciences Limited's strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's commitment to quality, regulatory compliance, and sustainability positions it as a trusted partner for pharmaceutical companies seeking reliable manufacturing solutions. Cohance's ongoing efforts to address regulatory observations and implement corrective actions demonstrate its dedication to continuous improvement and long-term growth.

Cohance Lifesciences Limited has a track record of supplying pharmaceutical products to various international markets. The company's export volume and consistency are supported by its compliance with international regulatory standards, including WHO and EU GMP. While the FDA's warning letter in January 2026 highlights areas for improvement, Cohance's commitment to corrective actions and quality assurance indicates a focus on maintaining reliability and trustworthiness as a supplier.

Importers should verify the following certifications when considering Cohance Lifesciences Limited as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

• WHO-GMP Certification: Verify the WHO Good Manufacturing Practices certification to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU Good Manufacturing Practices certification to confirm compliance with European regulatory requirements.

• ISO Certifications: Review ISO certifications related to quality management systems to assess the company's commitment to quality assurance.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Cohance Lifesciences Limited.

When conducting due diligence on Cohance Lifesciences Limited, consider the following steps:

• Regulatory Compliance: Review the company's compliance with international and national regulatory standards, including FDA, WHO, EU GMP, and ISO certifications.

• Quality Assurance: Assess the company's quality management systems and recent quality control reports to ensure product consistency and safety.

• Financial Stability: Examine the company's financial statements and credit history to evaluate its financial health and reliability as a